Lotus Technology Inc. announced that its CFO and Head of Capital Market will present at the Deutsche Bank ADR Virtual Investor Conference on November 12, 2026. The event offers investors a live, interactive platform to engage with the company. Recent highlights include Lotus Tech's full acquisition of Lotus UK, strategic collaborations in digital asset tokenization, a new electric vehicle lap record, and the unveiling of its Focus 2030 strategy aimed at sustainable growth. This presentation will provide insights into Lotus Tech's global integration and future plans.
Lotus Technology Inc. is presenting at the Deutsche Bank ADR Virtual Investor Conference on November 12, 2026. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 06, 2026 20:41 WIB: out of 134 priced US stocks, 40 rose and 90 fell. Notable movers include FNKO at USD 5.19 with a -15.33% change, ABNB at USD 194.00 with a +14.03% change, and PLBY at USD 1.37 with a +10.48% change.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
